SemPresto

Executive Summary

SemPresto is developing a novel, smartphone-attached autoinjector for emergency epinephrine administration in anaphylaxis. By integrating the device with a user's phone, the company aims to dramatically improve accessibility and adherence, addressing a critical gap where patients often fail to carry traditional injectors due to size or inconvenience. This innovation targets the $5B+ epinephrine autoinjector market, which has seen limited product innovation despite rising allergy prevalence. The company's device is designed for seamless daily carry, potentially reducing time-to-treatment during allergic emergencies. Founded in 2021 and based in San Francisco, SemPresto is in the early stages of product development and regulatory strategy. While specific funding and valuation details are undisclosed, the company's approach aligns with trends toward connected health devices and patient-centric design. Key milestones ahead include completing prototype validation, securing FDA clearance (likely via 510(k) pathway), and initiating clinical usability studies. A partnership with a pharmaceutical or distribution partner could accelerate market entry. SemPresto's success hinges on demonstrating safety, reliability, and user preference over existing solutions.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) Submission40% success
• Q1 2026Clinical Usability Study Results60% success
• Q3 2026Series A Funding Round50% success